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Letter to the Editor 
The retrospective analysis by Siegmann et al. seems to be 
based on a selection bias in favor of the 70.2 Gy group and, 
thus, the conclusion “…patients with decreasing PSA during 
SRT after RP should have a better outcome after receiving 70.2 
instead of the standard 66.6 Gy…” appears misleading.
As far as reported, PSA measurements during SRT were per-
formed from 2002 onwards, and patients with decreasing PSA 
during SRT received a total dose of 70.2 Gy (n = 67). The re-
maining patients (n = 234) consisted of patients with either 
stable or increasing PSA during SRT (as treated from 2002 
onwards), or probably with unknown PSA status during SRT 
(as treated before 2002). The latter patients were treated with 
a total dose of 66.6 Gy. 
Patients with decreasing PSA during SRT have most likely a 
higher chance of improved PSA outcome (e.g., undetectable PSA 
after SRT, long-term PSA control) as opposed to patients with 
unknown, stable, or even increasing PSA values during SRT due 
to several reasons, including decreased risk of disease outside the 
prostate bed and higher radiation responsiveness. Therefore, this 
selection bias favors the 70.2 Gy group – at least in part –irrespec-
tive of the applied total dose.
We recommend to include the information “PSA decrease 
during SRT yes vs. no” as a variable to the multivariable analysis 
to control for this bias and also to acknowledge the significantly 
shorter follow-up of the 70.2 Gy cohort (21 vs. 31.6 months) as a 
limitation. 
We agree with the authors that a prospective trial is needed 
and would like to refer to the Swiss Group for Clinical Cancer Re-
search (SAKK) Phase III trial 09/10 which is currently recruiting 
patients in Switzerland, Germany, and Hungary, comparing 64 Gy 
(equivalent to 66.6 Gy with 1.8 Gy single doses using an α/β ratio 
of 3 Gy) vs. 70 Gy in patients without macroscopic biochemical 
recurrence after prostatectomy [www.clinicaltrials.gov; identifier 
number NCT01272050]. The trial will include 250 patients and 
will hopefully clarify the question of dose intensification in the 
salvage radiotherapy setting after prostatectomy.
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Response by A. Siegmann1, D. Bottke2, J. Faehndrich1, et al.: 
Appropriate Selection is a Good Reason for Dose Escalation in Salvage Radiotherapy, SRT 
In their letter, Dr. Gadhjar et al. criticize selection bias in our 
SRT study [4], but do not offer in what respect the selection was 
flawed. They point out correctly that in our retrospective analysis, 
the PSA response during SRT was unknown for "early" patients 
and state that the selection favored the high-dose cohort. Indeed 
– and this is stated in our paper – the favorable factors of respond-
ers were the rationale for the selection. But, as is conceded in the 
letter, only a part of the advantage is attributable to these factors. 
A preliminary analysis of a larger cohort with PSA monitored dur-
ing SRT (but still a short follow-up) confirmed the positive effect 
for the high-dose group. 
We welcome the prospective trial of SAKK, analyzing dose 
escalation in SRT. However, the suggested equivalence of 64 Gy in 
2 Gy fractions to 66.6 Gy in 1.8 Gy fractions should be regarded 
with care. The α/β ratio of prostate cancer is still under discussion. 
Values below 2 have been suggested by Fowler and others [1, 2] 
and would result in a higher BED from the 2 Gy scheme. An α/β 
ratio as high as 30 [3] would have the opposite effect. It is also an 
issue to include and stratify patients with relevant risk parameters 
appropriately. 
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